Jason Harris

Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.

Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.

Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.

Birtamimab treatment led to longer survival in patients with Mayo Stage IV amyloid light chain amyloidosis at 9 month follow-up.

Experts believe that use of the Breast Cancer Index test in patients with early-stage, hormone receptor–positive breast cancer who are undergoing treatment with endocrine therapy may help to identify those who could be good candidates for the addition of ovarian function suppression.

Results from the LITESPARK-003 trial showed continued antitumor activity after 2 years with belzutifan plus cabozantinib.

Long-lasting duration of response and prolonged survival were observed following treatment with MEDI15752 vs pembrolizumab among patients with treatment-naïve nonsquamous non–small cell lung cancer, according to findings from a phase 1b/2 trial.

Progression-free survival and response results presented from the phase 3 TROPiCS-02 trial at 2022 ESMO indicated sacituzumab govitecan-hziy may be favorable vs physician’s choice of treatment for HER2-low or HER2 IHC0, hormone receptor¬–positive metastatic breast cancer.

Doses of Rhenium-186 nanoliposome above 100 Gy improved overall survival in recurrent glioma, according to results from the phase 1 ReSPECT-GBM trial presented at 2022 ESMO.

Positive trends in screening of patients at high risk of lung cancer may double survival in this malignancy, according to Giorgio V. Scagliotti, MD, PhD, at 2022 WCLC.

Ociperlimab plus tislelizumab showed promising antitumor activity in patients with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer who were treated on the phase 1 AdvanTig-105 trial.

Patients with advanced PD-L1–positive non–small cell lung cancer and squamous histology who were treated with sitravatinib plus tiselizumab had promising antitumor activity.

Response rates with temozolomide plus nivolumab in extensive-stage small cell lung cancer show promise.

Patients with stage IB to IIA non–small cell lung cancer who experienced a pathologic complete response to neoadjuvant nivolumab plus platinum-based doublet chemotherapy experienced a prolonged event-free survival.

Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.

The phase 2 KarMMA trial showed that certain characteristics were potentially linked to complete responses in patients with multiple myeloma.

A phase 2 trial reported a reduction in steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant.

Patients with metastatic castration-resistant prostate cancer who had a high genomic loss of heterozygosity may respond better to treatment with talazoparib.

Investigators of a phase 1/2 trial observed positive response outcomes with expanded natural killer cells plus AMF13 in patients with heavily pretreated lymphoma.

Early findings from the phase 1/2a TEM-GBM study presented at the 2022 AACR Annual Meeting displayed potential of temferon to affect the tumor microenvironment of glioblastoma.

Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.

The phase 2 CC-ANNIE trial was launched in China investigating anlotinib plus sintilimiab for recurrent platinum-resistant ovarian clear cell carcinoma.

Results from the TITAN trial that were presented at 2022 ASCO GU showed a link between deep PSA responses with apalutamide and patient-related outcomes.

Nivolumab in combination with chemotherapy was beneficial vs chemotherapy alone in patients with gastric or gastroesophageal junction cancer at a follow-up of at least 24 months.

The combination of acalabrutinib, with or without obinutuzumab, produced a strong survival benefit for patients with treatment-naïve chronic lymphocytic leukemia over treatment with ibrutinib or venetoclax plus obinutuzumab.

At 24 weeks, patients with myelofibrosis transfused with serum ferritin and receiving momelotinib experienced a treatment response.

Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.

Patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma had high rates of response and overall survival with axicabtagene ciloleucel at an updated analysis of the ZUMA-5 trial.

Circulating tumor DNA should be utilized early to help detect relapse in patients with triple-negative breast cancer.